Detail akcie GH Rsrch Rg online

Business Summary: GH Research PLC is a clinical-stage biopharmaceutical company. The Company is engaged in offering treatment for psychiatric and neurological disorders. The Company's pipeline includes GH001, GH002 and GH003. The Company focuses on developing its 5- Methoxy-N, N-Dimethyltryptamine, (5-MeO-DMT), therapies for the treatment of patients with Treatment Resistant Depression (TRD). Its product candidate, GH001, is formulated for 5-MeO-DMT administration via an inhalation approach. With GH001, the Company has completed two Phase 1 healthy volunteer clinical trials and a Phase 1/2 clinical trial in patients with treatment-resistant depression (TRD). The GH002 is a 5-MeO-DMT product candidate formulated for administration via an injectable approach. GH002 has completed pre-clinical development to support early clinical trials. The GH003 is a 5-MeO-DMT product candidate formulated for administration via an intranasal administration approach.
Financial Summary: BRIEF: For the nine months ended 30 September 2025, GH Research PLC revenues was not reported. Net loss increased 13% to $34.1M. Higher net loss reflects Biotechnology & Medical Research segment loss increase of 70% to $44M. Basic Earnings per Share excluding Extraordinary Items increased from -$0.58 to -$0.56.